Eris Lifesciences Limited – Investor Presentation Summary

Key Operational Highlights

  • Domestic Branded Formulations (DBF) Q1 FY27 organic growth of 14.2% year-over-year
  • 7 out of 10 therapy areas in the portfolio achieved double-digit growth rates in Q1
  • 85% of the portfolio consists of chronic & sub-chronic therapies
  • Insulin market share increased from 9% to 16% since Biocon acquisition
  • Sundae (semaglutide) achieved ₹12 crore in first full quarter in ₹88 crore generic market
  • Sundae holds 21% prescription share and 20% unit share in semaglutide market

Segment-wise Performance

  • Domestic Branded Formulations (DBF): Broad-based growth across therapies
  • Insulin: +27.7% growth
  • Derma: +11.3% growth
  • Onco+Nephro: +20.8% growth
  • CNS: +12.9% growth
  • VMN: +16.3% growth
  • Women's: +12.1% growth
  • Others: +10.9% growth
  • International Business (Swiss Parenterals): Base business remained largely uninterrupted with no EU contribution

Financial Highlights

  • Revenue: ₹873 crore (Q1 FY27 vs ₹773 crore Q1 FY26, +13.0% YoY)
  • EBITDA: ₹296 crore (Q1 FY27 vs ₹277 crore Q1 FY26, +7.1% YoY)
  • PAT: ₹143 crore (Q1 FY27 vs ₹125 crore Q1 FY26, +14.5% YoY)
  • EPS: ₹10.27 (Cash EPS: ₹13.52)
  • Margins: Gross Margin 72.6% (vs 76.1% Q1 FY26), EBITDA Margin 33.9% (vs 35.8% Q1 FY26), PAT Margin 16.4% (vs 16.2% Q1 FY26)
  • YoY comparison: Revenue +13.0%, EBITDA +7.1%, PAT +14.5%
  • Drivers of performance: Broad-based growth across therapy areas, increasing contribution of Biologics including Insulins and GLP-1
  • Effective Tax Rate: 20% (vs 22.5% in Q1 FY26)

Balance Sheet Snapshot

  • Capex: ₹88 crore in Q1 FY27
  • OCF/EBITDA: 77%
  • Net Debt/Equity: Not Specified
  • Financial Health Insights: Strong cash flow generation with 77% OCF/EBITDA ratio

Capex & Cash Flow Health

  • Capital Expenditure: ₹88 crore in Q1 FY27
  • Free Cash Flow: Not Specified
  • Operating Cash Flow: Not Specified
  • Investment Rationale: Focus on capacity expansion and technology upgrades

Strategic & R&D Initiatives

  • Eris Bionxt: Commercialization planned for control on supplies, margin improvement and leveraging fiscal benefits
  • Insulin Analogs: Planning entry into ₹2,309 crore market growing at 9.4%
  • Swiss Parenterals: Targeting Unit-3 commissioning in FY28 as per plan
  • EU CAPA Actions: Execution underway with sites to be audit ready by December 2026

Management Commentary & Growth Outlook

  • Strategic Outlook: Focus on six key priorities for next two quarters:

1. Get OAD segment to 70% of market growth (20% of portfolio)

2. Get Cardiac closer to market growth (second legacy engine)

3. Commercialize Eris Bionxt

4. Enter non-represented Insulin Analogs market

5. Maintain momentum for Sundae

6. Get both injectable sites audit ready

  • Risks and Opportunities: Possible margin contraction in FY27 for Swiss Parenterals, with better clarity expected after Q2 FY27

Shareholder Profile

  • Promoter Holding: 54.14% as of June 2026
  • Top Institutional Investors: LILAC INVESTMENTS LIMITED (8.63%), HDFC MUTUAL FUND (8.33%), FRANKLIN TEMPLETON MUTUAL FUND (4.29%)
  • Market Capitalization: ₹19,865 crore
  • Shares Outstanding: 13,85,78,489